Glaxo Launches Flonase OTC, Banks On More Consumer Growth Drivers
This article was originally published in The Tan Sheet
Executive Summary
CEO Andrew Witty says the consumer business GSK is forming through brand divestitures and its JV with Novartis is a part of “the company I've been trying to create for seven years.” GSK’s OTC Flonase reached U.S. stores Feb. 3, a sign of additional product launches he expects the consumer health JV to do.
You may also be interested in...
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.
Flonase Switch Approved, Branded Nasal Allergy Spray Market Will Grow In 2015
Glaxo says Flonase Allergy Relief (fluticasone propionate 50 mcg spray) is the “first OTC nasal spray indicated for relief of all nasal and eye-related allergy symptoms.” The firm has not learned from FDA whether Flonase Allergy Relief will launch with market exclusivity.
GSK Hones OTCs As “Sharp End” Of Consumer Products Business
Glaxo’s OTC business is “the very best end of consumer goods as opposed to being a poor relation of pharmaceuticals,” says Emma Walmsley, GSK Consumer Healthcare president.